Corvus Pharmaceuticals (CRVS) Key Ratios
$14.31
As on 28-Aug-2026 11:32EDT
Market cap
$1,216 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -44.86 | -115.68 | -14.40 | -12.20 | -4.41 |
| Net Profit | -31.16 | -124.54 | -19.93 | -15.06 | -249.08 |
| EPS | -27.80 | -89.07 | 8.39 | 7.82 | -294.19 |
| Book Value | -- | -- | 61.07 | -13.97 | -20.65 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -88.16 | -73.89 | -37.78 | -32.60 | -174.85 |
| Return on Capital
| -85.19 | -71.34 | -- | -31.90 | -168.93 |
| Return on Assets
| -59.39 | -53.81 | -30.85 | -21.83 | -108.85 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.02 | 0.03 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
--
|
-31.90
|
-168.93
|
-54.73
|
-51.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-37.78
Higher than Peers by 2.51
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
-37.78
|
-32.60
|
-174.85
|
-57.02
|
-53.90
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
-30.85
Lower than Peers by 0.01
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
-30.85
|
-21.83
|
-108.85
|
-47.51
|
-46.49
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-89.88
|
--
|
--
|
--
|
--
|
EBIT Growth
-14.40
Lower than Peers by 13.45
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
-14.40
|
75.47
|
-130.47
|
34.57
|
4.44
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
-19.93
Lower than Peers by 12.74
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
-19.93
|
75.47
|
-130.47
|
34.57
|
4.47
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
EPS Growth
8.39
Lower than Peers by 6.04
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
8.39
|
0.79
|
-0.65
|
0.38
|
0.04
|
|
Peer Median
|
14.43
|
--
|
--
|
--
|
--
|
Book Value Growth
136.49
Higher than Peers by 146.95
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
136.49
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.46
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
--
|
0.02
|
0.03
|
0.04
|
0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
0.00
|
0.01
|
0.01
|
0.04
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
16.16
Higher than Peers by 10.36
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
16.16
|
6.21
|
1.54
|
4.07
|
4.06
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
16.16
Higher than Peers by 10.47
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
16.16
|
--
|
--
|
--
|
4.13
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
-9.63
Lower than Peers by 7.54
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
-9.63
|
-6.10
|
-34.15
|
-17.06
|
-63.16
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
--
|
--
|
--
|
-1,777.87
|
-697.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
--
|
8,823.40
|
8,824.01
|
4,234.24
|
1,762.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
--
|
-40.18
|
-5.87
|
-3.19
|
-0.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
5.35
No difference
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
5.35
|
10.03
|
11.23
|
2.23
|
0.71
|
|
Peer Median
|
5.35
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.36
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
0.36
|
-36.78
|
-5.06
|
-2.25
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1,216
Higher than Peers by 1,069
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
1,216
|
--
|
--
|
--
|
--
|
|
Peer Median
|
147
|
--
|
--
|
--
|
--
|